COMMUNIQUÉS West-GlobeNewswire

Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
20/10/2018
In SOLAR-1 trial, BYL719 plus fulvestrant significantly improved PFS and ORR in these patients, following progression on or after an aromatase inhibitor with or without a CDK4/6 inhibitor, vs. fulvestrant alone[1] [...]
INNATE PHARMA : Phase II results from monalizumab/cetuximab in head and neck cancer at ESMO
20/10/2018
INNATE PHARMA ANNOUNCES PHASE II RESULTS FROM MONALIZUMAB AND CETUXIMAB COMBINATION IN HEAD AND NECK CANCER AT THE ESMO 2018 CONGRESS Confirmation of previously reported response rate and new data on durability of [...]
INNATE PHARMA : Résultats de phase II de monalizumab avec cetuximab dans les cancers de la tête et du cou à ESMO
20/10/2018
INNATE PHARMA ANNONCE DES RÉSULTATS DE PHASE II DE LA COMBINAISON DE MONALIZUMAB ET CETUXIMAB DANS LES CANCERS DE LA TÊTE ET DU COU AU CONGRÈS DE L'ESMO 2018 La confirmation du taux de réponse précédemment observé et [...]
Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
20/10/2018
- 70% overall response rate (33/47 patients) at 2 mg dose of SD-101 includes 17 additional patients - -Progression free survival, response rate in patients with PDL-1 negative tumors and biomarker activity supports [...]
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
20/10/2018
Overall Clinical Benefit Rate of 85%, Partial Response Rate of 42% and Progression Free Survival of 5.4 Months Observed in Patients with > 2 Prior Therapies and/or Prior Bevacizumab REDWOOD CITY, Calif., Oct. 20, [...]
TESARO Announces Data Presentations at ESMO 2018 Congress
20/10/2018
Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancer PRIMA safety data for individualized niraparib dose regimen presented Top- [...]
UPDATE – GrandOmics Biosciences Offers Genetic Test Using the Saphyr System for Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD) in China
20/10/2018
SAN DIEGO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural [...]
Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)
19/10/2018
FDA approves asthma indication for Dupixent ® (dupilumab) Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Only biologic approved for oral corticosteroid-dependent asthma, [...]
Sanofi : La FDA approuve l'indication de Dupixent® (dupilumab) dans l'asthme
19/10/2018
La FDA approuve l'indication de Dupixent ® (dupilumab) dans l'asthme Seul agent biologique approuvé pour le traitement de l'asthme modéré à sévère à phénotype éosinophilique Seul agent biologique approuvé pour le [...]
Syneos Health Schedules Third Quarter 2018 Earnings Call for Tuesday, November 6, 2018
19/10/2018
RALEIGH, N.C., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract [...]
Globus Medical Schedules Third Quarter 2018 Earnings Release and Conference Call
19/10/2018
AUDUBON, Pa., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2018 after [...]
Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in January 2017
19/10/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), announced today that its wholly owned subsidiary, Corsicanto II Designated Activity Company, a [...]
Correction of Press Release dated September 24, 2018 (‘Golden Leaf Holdings' Subsidiary, Medical Marijuana Group Corp, Acquires Sales License from Health Canada’)
19/10/2018
TORONTO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“Golden Leaf” or the “Company”) (CSE:GLH) (OTCQB:GLDFF) wishes to advise that the press release issued on September 24, 2018 contained an error [...]
GrandOmics Biosciences Offers Genetic Test Using the Saphyr System for Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD) in China
19/10/2018
SAN DIEGO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural [...]
Bespoke Extracts Sponsors Motorcycle Racer Sean Dylan Kelly at 35th Annual Race of Champions at Daytona International Speedway
19/10/2018
SUNNY ISLES, Fla., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Bespoke Extracts, Inc. (OTCQB: BSPK), producer of high quality, great tasting, hemp-derived CBD products, today announced that it will be a title sponsor of [...]
Nextech to Offer Educational Sessions and EMR Innovations at AAO 2018
19/10/2018
Nextech to present four in-booth sessions including a panel of electronic medical record (EMR) users to discuss industry trends, new functionalities and more TAMPA, Fla., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Nextech [...]
NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO
19/10/2018
NANOBIOTIX: POSITIVE PHASE II/III RESULTS FOR NBTXR3 IN SOFT TISSUE SARCOMA PRESENTED AT ESMO Dr. Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at Institut Curie - Paris, presented first-in-class [...]
NANOBIOTIX : Résultats positifs de la Phase II/III dans les Sarcomes des Tissus Mous avec NBTXR3 présentés à l’ESMO
19/10/2018
NANOBIOTIX : RESULTATS POSITIFS DE LA PHASE II/III DANS LES SARCOMES DES TISSUS MOUS AVEC NBTXR3 PRESENTES A L’ESMO Dr. Sylvie Bonvalot, Chef du Service Sarcomes et Tumeurs Complexes de l’Institut Curie (Paris), a [...]
Pediapharm annonce la clôture d’acquisitions transformatrices, de diversification et d’expansion de la plateforme pour une croissance future
19/10/2018
CE COMMUNIQUÉ NE PEUT ÊTRE DISTRIBUÉ AUX AGENCES DE TRANSMISSION AMÉRICAINES NI DIFFUSÉ AUX ÉTATS-UNIS. NE PAS RESPECTER CETTE CONSIGNE PEUT CONSTITUER UNE VIOLATION DE LA LOI SUR LES TITRES DES ÉTATS-UNIS. MONTRÉAL, 19 [...]

Pages